|
1
|
Karpathiou G, Dridi M, Krebs-Drouot L, Vassal F, Jouanneau E, Jacquesson T, Barrey C, Prades JM, Dumollard JM, Meyronet D, Boutonnat J, Péoc’h M. Autophagic Markers in Chordomas: Immunohistochemical Analysis and Comparison with the Immune Microenvironment of Chordoma Tissues. Cancers (Basel) 2021; 13:cancers13092169. [PMID: 33946484 PMCID: PMC8124629 DOI: 10.3390/cancers13092169] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Revised: 04/24/2021] [Accepted: 04/26/2021] [Indexed: 12/12/2022] Open
Abstract
Simple Summary In contrast to normal notochords, autophagic factors are often present in chordomas. Furthermore, PD-L1+ immune cells also express LC3B, suggesting the need for further investigations between autophagy and the immune microenvironment. Abstract Chordomas are notably resistant to chemotherapy. One of the cytoprotective mechanisms implicated in chemoresistance is autophagy. There are indirect data that autophagy could be implicated in chordomas, but its presence has not been studied in chordoma tissues. Sixty-one (61) chordomas were immunohistochemically studied for autophagic markers and their expression was compared with the expression in notochords, clinicopathological data, as well as the tumor immune microenvironment. All chordomas strongly and diffusely expressed cytoplasmic p62 (sequestosome 1, SQSTM1/p62), whereas 16 (26.2%) tumors also showed nuclear p62 expression. LC3B (Microtubule-associated protein 1A/1B-light chain 3B) tumor cell expression was found in 44 (72.1%) tumors. Autophagy-related 16‑like 1 (ATG16L1) was also expressed by most tumors. All tumors expressed mannose-6-phosphate/insulin-like growth factor 2 receptor (M6PR/IGF2R). LC3B tumor cell expression was negatively associated with tumor size, while no other parameters, such as age, sex, localization, or survival, were associated with the immunohistochemical factors studied. LC3B immune cell expression showed a significant positive association with programmed death-ligand 1 (PD-L1)+ immune cells and with a higher vascular density. ATG16L1 expression was also positively associated with higher vascular density. Notochords (n = 5) showed different immunostaining with a very weak LC3B and M6PR expression, and no p62 expression. In contrast to normal notochords, autophagic factors such as LC3B and ATG16L1 are often present in chordomas, associated with a strong and diffuse expression of p62, suggesting a blocked autophagic flow. Furthermore, PD-L1+ immune cells also express LC3B, suggesting the need for further investigations between autophagy and the immune microenvironment.
Collapse
Affiliation(s)
- Georgia Karpathiou
- Pathology Department, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; (M.D.); (J.M.D.); (M.P.)
- Correspondence:
| | - Maroa Dridi
- Pathology Department, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; (M.D.); (J.M.D.); (M.P.)
| | - Lila Krebs-Drouot
- Pathology Department, University Hospital of Grenoble, 38700 Grenoble, France; (L.K.-D.); (J.B.)
| | - François Vassal
- Neurosurgery Department, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France;
| | - Emmanuel Jouanneau
- Department of Neurosurgery B, Neurological Hospital Pierre Wertheimer, 69500 Lyon, France; (E.J.); (T.J.)
- Inserm U1052, CNRS UMR5286, «Signaling, Metabolism and Tumor Progression» The Cancer Research Center of Lyon, 69373 Lyon, France
- Claude Bernard University, Lyon 1, 69100 Lyon, France; (C.B.); (D.M.)
| | - Timothée Jacquesson
- Department of Neurosurgery B, Neurological Hospital Pierre Wertheimer, 69500 Lyon, France; (E.J.); (T.J.)
- Department of Anatomy, Faculté de Médecine Lyon-Est, Université de Lyon, Université Claude Bernard Lyon 1, 69100 Lyon, France
| | - Cédric Barrey
- Claude Bernard University, Lyon 1, 69100 Lyon, France; (C.B.); (D.M.)
- Department of Spine and Spinal Cord Surgery, Neurological Hospital Pierre Wertheimer, 69500 Lyon, France
| | - Jean Michel Prades
- Head and Neck Surgery Department, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France;
| | - Jean Marc Dumollard
- Pathology Department, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; (M.D.); (J.M.D.); (M.P.)
| | - David Meyronet
- Claude Bernard University, Lyon 1, 69100 Lyon, France; (C.B.); (D.M.)
- East Pathology Institute, Hospices Civils de Lyon, 69677 Lyon, France
- Cancer Research Center of Lyon, Cancer Cell Plasticity Department, 69373 Lyon, France
| | - Jean Boutonnat
- Pathology Department, University Hospital of Grenoble, 38700 Grenoble, France; (L.K.-D.); (J.B.)
| | - Michel Péoc’h
- Pathology Department, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; (M.D.); (J.M.D.); (M.P.)
| |
Collapse
|